TheraRadar
← Back
Data updated: Jun 28, 2026

PHARMADERM

Generics

PHARMADERM is a generic drug manufacturer focused on Dermatology.

1987
Since
13
Drugs
-
Trials
0
New Drugs (2yr)

PHARMADERM's Key Drugs

PHARMADERM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PHARMADERM's Recent FDA Approvals

New NDA/BLA approvals for PHARMADERM over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PHARMADERM's Therapeutic Areas

PHARMADERM's approved drugs and pipeline span 1 therapeutic area, led by Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Dermatology 100%
1 drugs

PHARMADERM's Top Competitors

PHARMADERM's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

PHARMADERM Pipeline Snapshot

Active clinical trials for PHARMADERM across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Dermatology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling